What caused the volume spike in ORPH.IR stock on 11 Feb 2026?

The spike likely reflects concentrated trading in a low-liquidity name. Volume hit **15,112.00** vs an average **192.00**, suggesting block trades, repositioning by funds, or pre-announcement buying. No confirmed corporate news was posted at close.

What are realistic short-term price levels to watch for ORPH.IR stock?

Watch **EUR 0.13** as immediate support and **EUR 0.17** as near resistance. Meyka AI's base case target is **EUR 0.20**. Low liquidity means these levels can be crossed quickly, so use tight risk controls.

How does Meyka AI rate ORPH.IR and what does that mean for investors?

Meyka AI rates ORPH.IR with a score out of 100 at **67.39** (Grade B, Suggestion: HOLD). The grade reflects benchmark, sector, growth and key metrics. This is informational and not financial advice; perform your own due diligence.

Are there major catalysts to move ORPH.IR stock higher?

Yes. Key catalysts include new human challenge study wins, data releases from the Disease in Motion platform, or larger pharma contracts. Sector flows in Healthcare and biotech sentiment will amplify moves.

EU Stocks

Volume spike close: ORPH.IR Open Orphan EURONEXT 11 Feb 2026 signals buyers

ByHuzaifa Zahoor February 12, 2026February 12, 2026

ORPH.IR stock closed on EURONEXT on 11 Feb 2026 at EUR 0.14 after a clear volume spike. Volume reached 15,112.00 versus an average of 192.00, a relative volume of 78.71, signalling a sharp rise in intraday trading interest. The spike occurred with no recorded price change for the session but attracted attention because Open Orphan Plc operates in healthcare biotech and has active clinical trial services. We review the drivers, valuation, and short-term trading levels for ORPH.IR stock and explain what the volume surge may mean for traders and investors.